• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

Disease Education

  1. Cardiovascular
  2. Metabolic
  3. Immunology
  4. Oncology
  5. Renal
  6. Respiratory
  7. Infection
  • Other Cardiovascular Diseases Explore Other Cardiovascular Diseases
  • Transthyretin-mediated Amyloidosis (ATTR) Explore Transthyretin-mediated Amyloidosis (ATTR)

Email Recipient

  1. Colleague
  2. Myself

Email Recipient

  1. Colleague
  2. Myself
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA) Explore Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Systemic Lupus Erythematosus (SLE) Explore Systemic Lupus Erythematosus (SLE)

Email Recipient

  1. Colleague
  2. Myself

WEBSITE

WEBSITE

HER2Know

HER2 IHC Testing in Solid Tumors


VIDEO

VIDEO

Exploring the patient journey and unmet needs in eTNBC

Although most patients with TNBC are diagnosed in the early-stage curative setting, significant unmet needs remain despite advancements in targeted treatments. It is essential to raise HCP awareness around these patients, who require more efficacious and tolerable therapy options compared to the current standard of care. Additionally, there is growing recognition of the need to enhance patient-centred care beyond treatment, addressing psychological well-being, social support and survivorship as integral components in the management of TNBC.

Explore the patient journey and unmet needs for patients with eTNBC with insights from Matteo Lambertini, an Associate Professor and Consultant in Medical Oncology, whose research specialises in breast cancer care, with a particular focus on the management of breast cancer and fertility preservation.

VIDEO

TNBC Unmet Need Campaign

Despite a number of exciting targeted-treatment advances in TNBC over the last decade, the majority of patients with mTNBC do not express the biomarkers necessary to benefit from these therapies, and even those who do may still be ineligible for treatment. Enhancing healthcare professionals' awareness of these patients' needs is essential as we strive for more effective and tolerable treatmentoptions.

Explore the unmet needs for patients with first-line mTNBC treatment with insights from Paolo Tarantino, a breast medical oncologist and clinical researcher, whose research focusses on the HER2 oncoprotein and the development of novel therapies that target multiple subtypes, including TNBC.


Email Recipient

  1. Colleague
  2. Myself

VIDEO

VIDEO

HER2 NSCLC Mutation MOD Animation

This video is a series of 3D animated videos on HER2 mutations in NSCLC.


  • Chronic Kidney Disease Explore Chronic Kidney Disease

Email Recipient

  1. Colleague
  2. Myself
  • Asthma Explore Asthma
  • Chronic Obstructive Pulmonary Disease Explore Chronic Obstructive Pulmonary Disease
  • Chronic Rhinosinusitis with Nasal Polyps Explore Chronic Rhinosinusitis with Nasal Polyps
  • EGPA Explore EGPA
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA) Explore Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • IC Configuration editor Explore IC Configuration editor
  • IC Configuration editor Explore IC Configuration editor

Email Recipient

  1. Colleague
  2. Myself

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2025 AstraZeneca. All rights reserved.

US-69609; US-91816; US-103094; US-106788

Last Updated 11/25

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Privacy Notice

Legal Notice

Cookie Preferences

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Pharma Logo

Privacy NoticeLegal NoticeCookie Preferences